NexgenRx Stock Price, News & Analysis (CVE:NXG)

C$0.23 -0.01 (-2.17 %)
(As of 11/17/2017 12:20 PM ET)
Previous CloseC$0.23
Today's RangeC$0.23 - C$0.23
52-Week RangeC$0.17 - C$0.35
Volume19,000 shs
Average Volume49,360 shs
Market CapitalizationC$14.42 million
P/E RatioN/A
Dividend YieldN/A
Beta0.3

About NexgenRx (CVE:NXG)

NexgenRx logoNexgenRx Inc. (NexgenRx) administers, adjudicates and pays drug, dental and other extended healthcare claims for the beneficiaries of health benefit plans underwritten by its customers, using computer software. The Company is engaged in the sale of its administration and health benefit claims adjudication services to organizations managing health benefit plans on behalf of plan sponsors, such as employers and associations, among others, and to the Canadian plan sponsors providing an Administrative Services Only (ASO) health benefit plan to their plan members. The health benefit claims include drug, dental, extended health and healthcare spending account claims. The Company sells its service on a fee-per-transaction basis, in addition to per member administration fees. The Company's Web-based product, theclaimsXchange.com, offers a platform, which allows various extended health providers to submit claims on behalf of their patients for benefits through a Web portal.


Industry, Sector and Symbol:
  • Industry: N/A
  • Sub-Industry: N/A
  • Sector: N/A
  • Symbol: CVE:NXG
  • CUSIP: N/A
  • Web: www.nexgenrx.com
Profitability:
  • Trailing EPS: C$0.01
  • Net Margins: -7.62%
  • Return on Equity: -56.53%
  • Return on Assets: -5.02%
Misc:
  • Outstanding Shares: 60,392,000
 
Frequently Asked Questions for NexgenRx (CVE:NXG)

What is NexgenRx's stock symbol?

NexgenRx trades on the Canadian Venture Exchange (CVE) under the ticker symbol "NXG."

Who are some of NexgenRx's key competitors?

Who are NexgenRx's key executives?

NexgenRx's management team includes the folowing people:

  • Thomas F. Corcoran, Chairman of the Board
  • Ronald C. Loucks, President, Chief Executive Officer, Director
  • Kelly Ehler CPA, Interim Chief Financial Officer
  • Patrick G. Crowley, Director
  • Barry J. Reiter, Director (Age 66)
  • Ralph Soberano, Director
  • David A. Rosenkrantz, Independent Director

How do I buy NexgenRx stock?

Shares of NexgenRx and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is NexgenRx's stock price today?

One share of NexgenRx stock can currently be purchased for approximately C$0.23.

How big of a company is NexgenRx?

NexgenRx has a market capitalization of C$14.42 million.

How can I contact NexgenRx?

NexgenRx's mailing address is 185 the West Mall Suite 600, ETOBICOKE, ON M9C 5L5, Canada. The company can be reached via phone at +1-416-6953393.


MarketBeat Community Rating for NexgenRx (CVE NXG)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  14 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  32
MarketBeat's community ratings are surveys of what our community members think about NexgenRx and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for NexgenRx (CVE:NXG) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Analysts' Consensus Price Target: N/A
Consensus Price Target History for NexgenRx (CVE:NXG)
Price Target History for NexgenRx (CVE:NXG)
Analysts' Ratings History for NexgenRx (CVE:NXG)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for NexgenRx (CVE:NXG)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for NexgenRx (CVE:NXG)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for NexgenRx (CVE:NXG)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NexgenRx (CVE NXG)
Insider Trades by Quarter for NexgenRx (CVE:NXG)
Insider Trades by Quarter for NexgenRx (CVE NXG)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/31/2017Paul Everett CrossettInsiderBuy16,000C$0.23C$3,680.00
10/27/2017Paul Everett CrossettInsiderBuy500C$0.21C$105.00
10/20/2017Paul Everett CrossettInsiderBuy20,000C$0.22C$4,400.00
10/6/2017Paul Everett CrossettInsiderBuy58,000C$0.22C$12,760.00
10/4/2017Paul Everett CrossettInsiderBuy1,500C$0.23C$345.00
9/26/2017Paul Everett CrossettInsiderBuy500C$0.23C$115.00
8/17/2017Paul Everett CrossettInsiderBuy500C$0.23C$115.00
8/9/2017Paul Everett CrossettInsiderBuy12,000C$0.23C$2,760.00
8/8/2017Paul Everett CrossettInsiderBuy14,500C$0.23C$3,335.00
8/4/2017Paul Everett CrossettInsiderBuy31,000C$0.24C$7,440.00
7/31/2017Paul Everett CrossettInsiderBuy45,500C$0.23C$10,465.00
7/18/2017Paul Everett CrossettInsiderBuy25,000C$0.24C$6,000.00
7/4/2017Paul Everett CrossettInsiderBuy40,000C$0.24C$9,600.00
6/28/2017Paul Everett CrossettInsiderBuy45,000C$0.24C$10,800.00
6/27/2017Paul Everett CrossettInsiderBuy40,000C$0.24C$9,600.00
6/20/2017Paul Everett CrossettInsiderBuy30,000C$0.24C$7,200.00
6/14/2017Paul Everett CrossettInsiderBuy25,000C$0.24C$6,000.00
6/8/2017Paul Everett CrossettInsiderBuy50,000C$0.24C$12,000.00
6/7/2017Paul Everett CrossettInsiderBuy25,000C$0.24C$6,000.00
6/6/2017Paul Everett CrossettInsiderBuy50,000C$0.24C$12,000.00
6/5/2017Paul Everett CrossettInsiderBuy108,000C$0.24C$25,920.00
4/5/2017Paul Everett CrossettInsiderBuy78,000C$0.24C$18,720.00
3/20/2017Paul Everett CrossettInsiderBuy500C$0.24C$120.00
3/15/2017Paul Everett CrossettInsiderBuy27,000C$0.25C$6,750.00
3/14/2017Paul Everett CrossettInsiderBuy101,000C$0.25C$25,250.00
2/28/2017Paul Everett CrossettInsiderBuy10,000C$0.25C$2,500.00
2/21/2017Paul Everett CrossettInsiderBuy23,000C$0.25C$5,750.00
2/16/2017Paul Everett CrossettInsiderBuy14,500C$0.24C$3,480.00
2/10/2017Paul Everett CrossettInsiderBuy110,500C$0.24C$26,520.00
2/9/2017Paul Everett CrossettInsiderBuy15,000C$0.26C$3,900.00
2/3/2017Paul Everett CrossettInsiderBuy16,500C$0.25C$4,125.00
2/1/2017Paul Everett CrossettInsiderBuy22,500C$0.25C$5,625.00
1/30/2017Paul Everett CrossettInsiderBuy500C$0.23C$115.00
1/27/2017Paul Everett CrossettInsiderBuy20,000C$0.23C$4,600.00
1/24/2017Paul Everett CrossettInsiderBuy20,000C$0.23C$4,600.00
1/23/2017Paul Everett CrossettInsiderBuy5,000C$0.23C$1,150.00
5/6/2016Paul Everett CrossettInsiderBuy61,000C$155.00C$9,455,000.00
3/15/2016Paul Everett CrossettInsiderBuy5,000C$0.16C$775.00
3/14/2016Paul Everett CrossettInsiderBuy50,000C$0.16C$7,750.00
3/10/2016Paul Everett CrossettInsiderBuy21,000C$0.15C$3,150.00
3/4/2016Paul Everett CrossettInsiderBuy75,000C$0.16C$11,625.00
3/2/2016Paul Everett CrossettInsiderBuy25,000C$0.16C$3,875.00
2/26/2016Paul Everett CrossettInsiderBuy23,000C$0.16C$3,565.00
2/25/2016Paul Everett CrossettInsiderBuy25,000C$0.16C$3,875.00
2/2/2016Paul Everett CrossettInsiderBuy25,000C$0.15C$3,750.00
1/26/2016Paul Everett CrossettInsiderBuy25,000C$0.16C$4,000.00
12/2/2015Paul Everett CrossettInsiderBuy5,000C$0.15C$750.00
11/30/2015Paul Everett CrossettInsiderBuy25,000C$0.17C$4,250.00
9/23/2015Ronald Campbell LoucksDirectorBuy100,000C$0.15C$15,000.00
6/30/2015Ronald Campbell LoucksDirectorBuy600,000C$0.17C$102,000.00
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for NexgenRx (CVE:NXG)
Latest Headlines for NexgenRx (CVE NXG)
Source:
No headlines for this company have been tracked by MarketBeat.com

Social Media

Financials

Financials are not available for this stock.

Chart

NexgenRx (CVE NXG) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.